Merck and Moderna announced encouraging results from phase 3 of their clinical trials on an experimental mRNA-based treatment for advanced melanoma. This personalized therapy, combined with the immunotherapy Keytruda, showed a significant improvement in relapse-free survival. The laboratories plan to present these results at a medical congress and seek marketing authorization.